TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling

Liam A. Hurst; Benjamin J. Dunmore; Lu Long; Alexi Crosby; Rafia Al-Lamki; John Deighton; Mark Southwood; Xudong Yang; Marko Z. Nikolic; Blanca Herrera; Gareth J. Inman; John R. Bradley; Amer A. Rana; Paul D. Upton; Nicholas W. Morrell

doi:10.1038/ncomms14079

TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling

Liam A. Hurst, Benjamin J. Dunmore, Lu Long, Alexi Crosby, Rafia Al-Lamki, John Deighton, Mark Southwood, Xudong Yang, Marko Z. Nikolic, Blanca Herrera, Gareth J. Inman, John R. Bradley, Amer A. Rana, Paul D. Upton (Lead / Corresponding author), Nicholas W. Morrell (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

200 Citations (Scopus)

429 Downloads (Pure)

Abstract

Heterozygous germ-line mutations in the bone morphogenetic protein type-II receptor (BMPR-II) gene underlie heritable pulmonary arterial hypertension (HPAH). Although inflammation promotes PAH, the mechanisms by which inflammation and BMPR-II dysfunction conspire to cause disease remain unknown. Here we identify that tumour necrosis factor-α (TNFα) selectively reduces BMPR-II transcription and mediates post-translational BMPR-II cleavage via the sheddases, ADAM10 and ADAM17 in pulmonary artery smooth muscle cells (PASMCs). TNFα-mediated suppression of BMPR-II subverts BMP signalling, leading to BMP6-mediated PASMC proliferation via preferential activation of an ALK2/ACTR-IIA signalling axis. Furthermore, TNFα, via SRC family kinases, increases pro-proliferative NOTCH2 signalling in HPAH PASMCs with reduced BMPR-II expression. We confirm this signalling switch in rodent models of PAH and demonstrate that anti-TNFα immunotherapy reverses disease progression, restoring normal BMP/NOTCH signalling. Collectively, these findings identify mechanisms by which BMP and TNFα signalling contribute to disease, and suggest a tractable approach for therapeutic intervention in PAH.

Original language	English
Article number	14079
Pages (from-to)	1-14
Number of pages	14
Journal	Nature Communications
Volume	8
DOIs	https://doi.org/10.1038/ncomms14079
Publication status	Published - 13 Jan 2017

Access to Document

10.1038/ncomms14079Licence: CC BY

Final Published Version
Copyright The Author(s) 2017. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Final published version, 2.82 MBLicence: CC BY

Cite this

Hurst, L. A., Dunmore, B. J., Long, L., Crosby, A., Al-Lamki, R., Deighton, J., Southwood, M., Yang, X., Nikolic, M. Z., Herrera, B., Inman, G. J., Bradley, J. R., Rana, A. A., Upton, P. D., & Morrell, N. W. (2017). TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling. Nature Communications, 8, 1-14. Article 14079. https://doi.org/10.1038/ncomms14079

@article{44c54b3111ac4423913df4e3d0f31507,

title = "TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling",

abstract = "Heterozygous germ-line mutations in the bone morphogenetic protein type-II receptor (BMPR-II) gene underlie heritable pulmonary arterial hypertension (HPAH). Although inflammation promotes PAH, the mechanisms by which inflammation and BMPR-II dysfunction conspire to cause disease remain unknown. Here we identify that tumour necrosis factor-α (TNFα) selectively reduces BMPR-II transcription and mediates post-translational BMPR-II cleavage via the sheddases, ADAM10 and ADAM17 in pulmonary artery smooth muscle cells (PASMCs). TNFα-mediated suppression of BMPR-II subverts BMP signalling, leading to BMP6-mediated PASMC proliferation via preferential activation of an ALK2/ACTR-IIA signalling axis. Furthermore, TNFα, via SRC family kinases, increases pro-proliferative NOTCH2 signalling in HPAH PASMCs with reduced BMPR-II expression. We confirm this signalling switch in rodent models of PAH and demonstrate that anti-TNFα immunotherapy reverses disease progression, restoring normal BMP/NOTCH signalling. Collectively, these findings identify mechanisms by which BMP and TNFα signalling contribute to disease, and suggest a tractable approach for therapeutic intervention in PAH.",

author = "Hurst, \{Liam A.\} and Dunmore, \{Benjamin J.\} and Lu Long and Alexi Crosby and Rafia Al-Lamki and John Deighton and Mark Southwood and Xudong Yang and Nikolic, \{Marko Z.\} and Blanca Herrera and Inman, \{Gareth J.\} and Bradley, \{John R.\} and Rana, \{Amer A.\} and Upton, \{Paul D.\} and Morrell, \{Nicholas W.\}",

note = "This work was supported by grants from the British Heart Foundation, RG/13/4/30107 (N.W.M.), CH/09/001/25945 (N.W.M.), a Medical Research Council Experimental Challenge Award (N.W.M.), a Fondation Leducq Transatlantic Network of Excellence (N.W.M.), the Dinosaur Trust (A.R.) and a UK National Institute for Health Research Healthcare Science Fellowship (M.S.). L.A.H. was funded through a BHF PhD student programme (FS/09/050). The UK National Institute for Health Research Cambridge Biomedical Research Centre and Cell Phenotyping Hub provided infrastructure support.",

year = "2017",

month = jan,

day = "13",

doi = "10.1038/ncomms14079",

language = "English",

volume = "8",

pages = "1--14",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

}

Hurst, LA, Dunmore, BJ, Long, L, Crosby, A, Al-Lamki, R, Deighton, J, Southwood, M, Yang, X, Nikolic, MZ, Herrera, B, Inman, GJ, Bradley, JR, Rana, AA, Upton, PD & Morrell, NW 2017, 'TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling', Nature Communications, vol. 8, 14079, pp. 1-14. https://doi.org/10.1038/ncomms14079

TY - JOUR

T1 - TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling

AU - Hurst, Liam A.

AU - Dunmore, Benjamin J.

AU - Long, Lu

AU - Crosby, Alexi

AU - Al-Lamki, Rafia

AU - Deighton, John

AU - Southwood, Mark

AU - Yang, Xudong

AU - Nikolic, Marko Z.

AU - Herrera, Blanca

AU - Inman, Gareth J.

AU - Bradley, John R.

AU - Rana, Amer A.

AU - Upton, Paul D.

AU - Morrell, Nicholas W.

N1 - This work was supported by grants from the British Heart Foundation, RG/13/4/30107 (N.W.M.), CH/09/001/25945 (N.W.M.), a Medical Research Council Experimental Challenge Award (N.W.M.), a Fondation Leducq Transatlantic Network of Excellence (N.W.M.), the Dinosaur Trust (A.R.) and a UK National Institute for Health Research Healthcare Science Fellowship (M.S.). L.A.H. was funded through a BHF PhD student programme (FS/09/050). The UK National Institute for Health Research Cambridge Biomedical Research Centre and Cell Phenotyping Hub provided infrastructure support.

PY - 2017/1/13

Y1 - 2017/1/13

N2 - Heterozygous germ-line mutations in the bone morphogenetic protein type-II receptor (BMPR-II) gene underlie heritable pulmonary arterial hypertension (HPAH). Although inflammation promotes PAH, the mechanisms by which inflammation and BMPR-II dysfunction conspire to cause disease remain unknown. Here we identify that tumour necrosis factor-α (TNFα) selectively reduces BMPR-II transcription and mediates post-translational BMPR-II cleavage via the sheddases, ADAM10 and ADAM17 in pulmonary artery smooth muscle cells (PASMCs). TNFα-mediated suppression of BMPR-II subverts BMP signalling, leading to BMP6-mediated PASMC proliferation via preferential activation of an ALK2/ACTR-IIA signalling axis. Furthermore, TNFα, via SRC family kinases, increases pro-proliferative NOTCH2 signalling in HPAH PASMCs with reduced BMPR-II expression. We confirm this signalling switch in rodent models of PAH and demonstrate that anti-TNFα immunotherapy reverses disease progression, restoring normal BMP/NOTCH signalling. Collectively, these findings identify mechanisms by which BMP and TNFα signalling contribute to disease, and suggest a tractable approach for therapeutic intervention in PAH.

AB - Heterozygous germ-line mutations in the bone morphogenetic protein type-II receptor (BMPR-II) gene underlie heritable pulmonary arterial hypertension (HPAH). Although inflammation promotes PAH, the mechanisms by which inflammation and BMPR-II dysfunction conspire to cause disease remain unknown. Here we identify that tumour necrosis factor-α (TNFα) selectively reduces BMPR-II transcription and mediates post-translational BMPR-II cleavage via the sheddases, ADAM10 and ADAM17 in pulmonary artery smooth muscle cells (PASMCs). TNFα-mediated suppression of BMPR-II subverts BMP signalling, leading to BMP6-mediated PASMC proliferation via preferential activation of an ALK2/ACTR-IIA signalling axis. Furthermore, TNFα, via SRC family kinases, increases pro-proliferative NOTCH2 signalling in HPAH PASMCs with reduced BMPR-II expression. We confirm this signalling switch in rodent models of PAH and demonstrate that anti-TNFα immunotherapy reverses disease progression, restoring normal BMP/NOTCH signalling. Collectively, these findings identify mechanisms by which BMP and TNFα signalling contribute to disease, and suggest a tractable approach for therapeutic intervention in PAH.

U2 - 10.1038/ncomms14079

DO - 10.1038/ncomms14079

M3 - Article

C2 - 28084316

SN - 2041-1723

VL - 8

SP - 1

EP - 14

JO - Nature Communications

JF - Nature Communications

M1 - 14079

ER -

TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling

Abstract

Access to Document

Fingerprint

Cite this